University Of Tasmania
Browse
2018, ChemMedChem.pdf (811.77 kB)

Progress in the development of Platelet-Activating Factor Receptor (PAFr) antagonists and applications in the treatment of inflammatory diseases

Download (811.77 kB)
journal contribution
posted on 2023-05-19, 20:29 authored by Hyland, IK, O'Toole, RF, Jason SmithJason Smith, Alexander BissemberAlexander Bissember
Platelet-activating factor (PAF) and its receptor (PAFr) have been implicated in a wide range of diseases and disorders that originate from the activation of inflammatory pathways. Although the exact structure of the binding site on the PAFr remains unknown, the PAFr is a well-established therapeutic target, and an array of structurally diverse PAFr antagonists have been identified. These include compounds that are structurally similar to the natural PAF ligand, synthetic heterocycles, complex polycyclic natural products, and various metal complexes. This review provides an update on more than 20 years of progress in this area. The development and synthesis of new PAFr antagonists, structure-activity relationship studies, the biological activity of these molecules, and their therapeutic potential are discussed.

History

Publication title

ChemMedChem

Volume

13

Issue

18

Pagination

1873-1884

ISSN

1860-7179

Department/School

School of Natural Sciences

Publisher

Wiley-VCH

Place of publication

Germany

Rights statement

Copyright 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

Repository Status

  • Restricted

Socio-economic Objectives

Human pharmaceutical treatments

Usage metrics

    University Of Tasmania

    Exports